{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:20:22Z","timestamp":1785543622922,"version":"3.56.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UH2CA262220"],"award-info":[{"award-number":["UH2CA262220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UH2CA262220"],"award-info":[{"award-number":["UH2CA262220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UH2CA262220"],"award-info":[{"award-number":["UH2CA262220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UH2CA262220"],"award-info":[{"award-number":["UH2CA262220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UH2CA262220"],"award-info":[{"award-number":["UH2CA262220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-00889-7","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T11:46:45Z","timestamp":1751543205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers"],"prefix":"10.1038","volume":"9","author":[{"given":"Emily L.","family":"Hoskins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raven","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie W.","family":"Reeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele R.","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Samorodnitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altan","family":"Turkoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Breuning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Risch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilnelly M.","family":"Hernandez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Churchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Single","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cavnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Reilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Scaife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Nepple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Edge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodour","family":"Salhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Leiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha M.","family":"Wise-Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameek","family":"Roychowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"889_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jnci\/djk179","volume":"99","author":"M Hashibe","year":"2007","unstructured":"Hashibe, M. et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J. Natl. Cancer Inst. 99, 777\u2013789 (2007).","journal-title":"J. Natl. Cancer Inst."},{"key":"889_CR2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/1055-9965.EPI-05-0983","volume":"15","author":"NK Proia","year":"2006","unstructured":"Proia, N. K. et al. Smoking and smokeless tobacco-associated human buccal cell mutations and their association with oral cancer-a review. Cancer Epidemiol. Biomark. Prev. 15, 1061\u20131077 (2006).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"889_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3389\/fonc.2019.00815","volume":"9","author":"SF Oosting","year":"2019","unstructured":"Oosting, S. F. & Haddad, R. I. Best practice in systemic therapy for head and neck squamous cell carcinoma. Front. Oncol. 9, 815 (2019).","journal-title":"Front. Oncol."},{"key":"889_CR4","first-page":"75","volume":"34","author":"S Krishnamurthy","year":"2022","unstructured":"Krishnamurthy, S. et al. The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey. Clin. Transl. Radiat. Oncol. 34, 75\u201381 (2022).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"889_CR5","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-21-3849","volume":"28","author":"CH Chung","year":"2022","unstructured":"Chung, C. H. et al. Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and\/or metastatic head and neck squamous cell carcinoma. Clin. Cancer Res. 28, 2329\u20132338 (2022).","journal-title":"Clin. Cancer Res."},{"key":"889_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21\u201328 (2010).","journal-title":"Lancet Oncol."},{"key":"889_CR7","doi-asserted-by":"publisher","first-page":"705096","DOI":"10.3389\/fimmu.2021.705096","volume":"12","author":"A Botticelli","year":"2021","unstructured":"Botticelli, A. et al. Anti-PD-1 and anti-PD-L1 in head and neck cancer: a network meta-analysis. Front. Immunol. 12, 705096 (2021).","journal-title":"Front. Immunol."},{"key":"889_CR8","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.21037\/atm.2019.03.58","volume":"7","author":"JM Bauml","year":"2019","unstructured":"Bauml, J. M., Aggarwal, C. & Cohen, R. B. Immunotherapy for head and neck cancer: where are we now and where are we going?. Ann. Transl. Med. 7, S75 (2019).","journal-title":"Ann. Transl. Med."},{"key":"889_CR9","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1200\/EDBK_157801","volume":"35","author":"N Hashemi-Sadraei","year":"2016","unstructured":"Hashemi-Sadraei, N., Sikora, A. G. & Brizel, D. M. Immunotherapy and checkpoint inhibitors in recurrent and metastatic head and neck cancer. Am. Soc. Clin. Oncol. Educ. Book 35, e277\u2013e282 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"889_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","volume":"22","author":"AG Sacco","year":"2021","unstructured":"Sacco, A. G. et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 22, 883\u2013892 (2021).","journal-title":"Lancet Oncol."},{"key":"889_CR11","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/1078-0432.CCR-22-3886","volume":"29","author":"S Gulati","year":"2023","unstructured":"Gulati, S. et al. Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, nonrandomized, phase II clinical trial. Clin. Cancer Res. 29, 1906\u20131915 (2023).","journal-title":"Clin. Cancer Res."},{"key":"889_CR12","doi-asserted-by":"crossref","unstructured":"Shah, P. A., et al. NOTCH1 signaling in head and neck squamous cell carcinoma. Cells 9, 2677 (2020).","DOI":"10.3390\/cells9122677"},{"key":"889_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.0.CO;2-R","volume":"77","author":"X Shao","year":"1998","unstructured":"Shao, X. et al. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int. J. Cancer 77, 684\u2013688 (1998).","journal-title":"Int. J. Cancer"},{"key":"889_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0165-4608(01)00509-X","volume":"132","author":"M Poetsch","year":"2002","unstructured":"Poetsch, M., Lorenz, G. & Kleist, B. Detection of new PTEN\/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet. Cytogenet. 132, 20\u201324 (2002).","journal-title":"Cancer Genet. Cytogenet."},{"key":"889_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","volume":"3","author":"VW Lui","year":"2013","unstructured":"Lui, V. W. et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3, 761\u2013769 (2013).","journal-title":"Cancer Discov."},{"key":"889_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neo.2015.01.003","volume":"17","author":"M Sen","year":"2015","unstructured":"Sen, M. et al. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia 17, 256\u2013264 (2015).","journal-title":"Neoplasia"},{"key":"889_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/his.15099","volume":"84","author":"YH Chu","year":"2024","unstructured":"Chu, Y. H. et al. FGFR1\/2\/3-rearranged carcinoma of the head and neck: expanded histological spectrum crossing path with high-risk HPV in the sinonasal tract. Histopathology 84, 589\u2013600 (2024).","journal-title":"Histopathology"},{"key":"889_CR18","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.4161\/15384047.2014.961874","volume":"15","author":"L Yuan","year":"2014","unstructured":"Yuan, L. et al. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol. Ther. 15, 1613\u20131621 (2014).","journal-title":"Cancer Biol. Ther."},{"key":"889_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00428-016-1905-1","volume":"468","author":"D Brauswetter","year":"2016","unstructured":"Brauswetter, D. et al. Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma. Virchows Arch. 468, 579\u2013587 (2016).","journal-title":"Virchows Arch."},{"key":"889_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","volume":"21","author":"TY Seiwert","year":"2015","unstructured":"Seiwert, T. Y. et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21, 632\u2013641 (2015).","journal-title":"Clin. Cancer Res."},{"key":"889_CR21","doi-asserted-by":"publisher","first-page":"813732","DOI":"10.3389\/fimmu.2022.813732","volume":"13","author":"S Dou","year":"2022","unstructured":"Dou, S. et al. EGFR mutation and 11q13 amplification are potential predictive biomarkers for immunotherapy in head and neck squamous cell carcinoma. Front. Immunol. 13, 813732 (2022).","journal-title":"Front. Immunol."},{"key":"889_CR22","doi-asserted-by":"publisher","first-page":"e2200211","DOI":"10.1200\/PO.22.00211","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman, N. et al. HRAS mutations define a distinct subgroup in head and neck squamous cell carcinoma. JCO Precis Oncol. 7, e2200211 (2023).","journal-title":"JCO Precis Oncol."},{"key":"889_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","volume":"12","author":"A Friedlaender","year":"2024","unstructured":"Friedlaender, A. et al. Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark. Res. 12, 24 (2024).","journal-title":"Biomark. Res."},{"key":"889_CR24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.annonc.2021.04.003","volume":"32","author":"A Haslam","year":"2021","unstructured":"Haslam, A., Kim, M. S. & Prasad, V. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Ann. Oncol. 32, 926\u2013932 (2021).","journal-title":"Ann. Oncol."},{"key":"889_CR25","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","volume":"14","author":"JP Koivunen","year":"2008","unstructured":"Koivunen, J. P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275\u20134283 (2008).","journal-title":"Clin. Cancer Res."},{"key":"889_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","volume":"21","author":"A Drilon","year":"2020","unstructured":"Drilon, A. et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 261\u2013270 (2020).","journal-title":"Lancet Oncol."},{"key":"889_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 12, 402\u2013415 (2022).","journal-title":"Cancer Discov."},{"key":"889_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"889_CR29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy, S. M. Pemigatinib: first approval. Drugs 80, 923\u2013929 (2020).","journal-title":"Drugs"},{"key":"889_CR30","doi-asserted-by":"crossref","unstructured":"Cascetta, P. et al. RET inhibitors in non-small-cell lung cancer. Cancers 13, 4415 (2021).","DOI":"10.3390\/cancers13174415"},{"key":"889_CR31","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1038\/s41598-023-31055-3","volume":"13","author":"S O\u2019Haire","year":"2023","unstructured":"O\u2019Haire, S. et al. Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours. Sci. Rep. 13, 4116 (2023).","journal-title":"Sci. Rep."},{"key":"889_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21037\/tlcr-21-888","volume":"11","author":"A Di Federico","year":"2022","unstructured":"Di Federico, A. et al. EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature. Transl. Lung Cancer Res.11, 497\u2013503 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"889_CR33","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.29825","volume":"138","author":"JS Ross","year":"2016","unstructured":"Ross, J. S. et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int. J. Cancer 138, 881\u2013890 (2016).","journal-title":"Int. J. Cancer"},{"key":"889_CR34","doi-asserted-by":"publisher","first-page":"107469","DOI":"10.1016\/j.lungcan.2024.107469","volume":"188","author":"SV Liu","year":"2024","unstructured":"Liu, S. V. et al. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions. Lung Cancer 188, 107469 (2024).","journal-title":"Lung Cancer"},{"key":"889_CR35","doi-asserted-by":"publisher","first-page":"153303382211399","DOI":"10.1177\/15330338221139981","volume":"21","author":"SG Fang","year":"2022","unstructured":"Fang, S. G. et al. BCL6-SPECC1L: a novel fusion gene in nasopharyngeal carcinoma. Technol. Cancer Res. Treat. 21, 15330338221139981 (2022).","journal-title":"Technol. Cancer Res. Treat."},{"key":"889_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1101\/gr.156224.113","volume":"24","author":"A Valouev","year":"2014","unstructured":"Valouev, A. et al. Discovery of recurrent structural variants in nasopharyngeal carcinoma. Genome. Res. 24, 300\u2013309 (2014).","journal-title":"Genome. Res."},{"key":"889_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/path.4240","volume":"231","author":"GT Chung","year":"2013","unstructured":"Chung, G. T. et al. Identification of a recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated nasopharyngeal carcinoma. J. Pathol. 231, 158\u2013167 (2013).","journal-title":"J. Pathol."},{"key":"889_CR38","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/s41379-021-00846-2","volume":"34","author":"YJ Kuo","year":"2021","unstructured":"Kuo, Y. J. et al. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology. Mod. Pathol. 34, 1820\u20131830 (2021).","journal-title":"Mod. Pathol."},{"key":"889_CR39","doi-asserted-by":"publisher","first-page":"e24377","DOI":"10.1097\/MD.0000000000024377","volume":"100","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: a case report. Medecine100, e24377 (2021).","journal-title":"Medecine"},{"key":"889_CR40","doi-asserted-by":"publisher","first-page":"1654724","DOI":"10.1155\/2019\/1654724","volume":"2019","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Interfering expression of chimeric transcript SEPT7P2-PSPH promotes cell proliferation in patients with nasopharyngeal carcinoma. J. Oncol. 2019, 1654724 (2019).","journal-title":"J. Oncol."},{"key":"889_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/1078-0432.CCR-17-0352","volume":"24","author":"Q Zhong","year":"2018","unstructured":"Zhong, Q. et al. The RARS-MAD1L1 fusion gene induces cancer stem cell-like properties and therapeutic resistance in nasopharyngeal carcinoma. Clin. Cancer Res. 24, 659\u2013673 (2018).","journal-title":"Clin. Cancer Res."},{"key":"889_CR42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s12105-020-01249-6","volume":"15","author":"J Bubola","year":"2021","unstructured":"Bubola, J. et al. A poorly differentiated non-keratinizing sinonasal squamous cell carcinoma with a novel ETV6-TNFRSF8 fusion gene. Head. Neck Pathol. 15, 1284\u20131288 (2021).","journal-title":"Head. Neck Pathol."},{"key":"889_CR43","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"MS Lawrence","year":"2015","unstructured":"Lawrence, M. S. et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576\u2013582 (2015).","journal-title":"Nature"},{"key":"889_CR44","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/nar\/gkq622","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K. et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 38, e178 (2010).","journal-title":"Nucleic Acids Res."},{"key":"889_CR45","doi-asserted-by":"crossref","unstructured":"Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576\u2013582 (2015).","DOI":"10.1038\/nature14129"},{"key":"889_CR46","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1038\/ncomms5846","volume":"5","author":"N Stransky","year":"2014","unstructured":"Stransky, N. et al. The landscape of kinase fusions in cancer. Nat. Commun. 5, 4846 (2014).","journal-title":"Nat. Commun."},{"key":"889_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13059-019-1842-9","volume":"20","author":"BJ Haas","year":"2019","unstructured":"Haas, B. J. et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 20, 213 (2019).","journal-title":"Genome Biol."},{"key":"889_CR48","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/1741826711404502","volume":"19","author":"H Keller","year":"2012","unstructured":"Keller, H. et al. Arriba: effects of an educational intervention on prescribing behaviour in prevention of CVD in general practice. Eur. J. Prev. Cardiol. 19, 322\u2013329 (2012).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"889_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao, Q. et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 23, 227\u2013238.e3 (2018).","journal-title":"Cell Rep."},{"key":"889_CR50","doi-asserted-by":"crossref","unstructured":"Krook, M. A., et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb. Mol. Case Stud. 5, a004002 (2019).","DOI":"10.1101\/mcs.a004002"},{"key":"889_CR51","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson, B. D. et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat. Commun. 10, 2977 (2019).","journal-title":"Nat. Commun."},{"key":"889_CR52","doi-asserted-by":"publisher","first-page":"936952","DOI":"10.3389\/fonc.2022.936952","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang, C. et al. Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer. Front. Oncol. 12, 936952 (2022).","journal-title":"Front. Oncol."},{"key":"889_CR53","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","volume":"7","author":"S Palakurthi","year":"2019","unstructured":"Palakurthi, S. et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol. Res. 7, 1457\u20131471 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"889_CR54","doi-asserted-by":"crossref","unstructured":"Lee, H. W. & Seo, H. K. Fibroblast growth factor inhibitors for treating locally advanced\/metastatic bladder urothelial carcinomas via dual targeting of tumor-specific oncogenic signaling and the tumor immune microenvironment. Int. J. Mol. Sci. 22, 9526 (2021).","DOI":"10.3390\/ijms22179526"},{"key":"889_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","volume":"22","author":"R Ruan","year":"2023","unstructured":"Ruan, R. et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment. Mol. Cancer 22, 60 (2023).","journal-title":"Mol. Cancer"},{"key":"889_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","volume":"5","author":"CB Westphalen","year":"2021","unstructured":"Westphalen, C. B. et al. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis. Oncol. 5, 69 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"889_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","volume":"7","author":"V Parimi","year":"2023","unstructured":"Parimi, V. et al. Genomic landscape of 891 RET fusions detected across diverse solid tumor types. NPJ Precis. Oncol. 7, 10 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"889_CR58","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.esmoop.2022.100641","volume":"7","author":"K Murugesan","year":"2022","unstructured":"Murugesan, K. et al. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open 7, 100641 (2022).","journal-title":"ESMO Open"},{"key":"889_CR59","doi-asserted-by":"crossref","unstructured":"Pagani, F. et al. The landscape of actionable gene fusions in colorectal cancer. Int. J. Mol. Sci. 20, 5319 (2019).","DOI":"10.3390\/ijms20215319"},{"key":"889_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.trecan.2024.01.009","volume":"10","author":"A Gkountakos","year":"2024","unstructured":"Gkountakos, A. et al. Fusion genes in pancreatic tumors. Trends Cancer 10, 430\u2013443 (2024).","journal-title":"Trends Cancer"},{"key":"889_CR61","doi-asserted-by":"publisher","first-page":"107317","DOI":"10.1016\/j.lungcan.2023.107317","volume":"184","author":"H Seker-Cin","year":"2023","unstructured":"Seker-Cin, H. et al. Analysis of rare fusions in NSCLC: genomic architecture and clinical implications. Lung Cancer 184, 107317 (2023).","journal-title":"Lung Cancer"},{"key":"889_CR62","doi-asserted-by":"publisher","first-page":"1115405","DOI":"10.3389\/fonc.2023.1115405","volume":"13","author":"L Schubert","year":"2023","unstructured":"Schubert, L. et al. ERBB family fusions are recurrent and actionable oncogenic targets across cancer types. Front. Oncol. 13, 1115405 (2023).","journal-title":"Front. Oncol."},{"key":"889_CR63","doi-asserted-by":"crossref","unstructured":"Nair, S., J. A. Bonner, & Bredel, M. EGFR mutations in head and neck squamous cell carcinoma. Int. J. Mol. Sci. 23, 3818 (2022).","DOI":"10.3390\/ijms23073818"},{"key":"889_CR64","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12957-024-03463-w","volume":"22","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome. World J. Surg. Oncol. 22, 194 (2024).","journal-title":"World J. Surg. Oncol."},{"key":"889_CR65","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1634\/theoncologist.2019-0405","volume":"25","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. A rare EGFR-SEPT14 fusion in a patient with colorectal adenocarcinoma responding to erlotinib. Oncologist 25, 203\u2013207 (2020).","journal-title":"Oncologist"},{"key":"889_CR66","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/PPO.0000000000000615","volume":"28","author":"Z Wang","year":"2022","unstructured":"Wang, Z. & Anderson, K. S. Therapeutic targeting of FGFR signaling in head and neck cancer. Cancer J. 28, 354\u2013362 (2022).","journal-title":"Cancer J."},{"key":"889_CR67","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant, S. et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 24, 925\u2013935 (2023).","journal-title":"Lancet Oncol."},{"key":"889_CR68","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","volume":"30","author":"J Rod\u00f3n","year":"2024","unstructured":"Rod\u00f3n, J. et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat. Med. 30, 1645\u20131654 (2024).","journal-title":"Nat. Med."},{"key":"889_CR69","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann. Oncol. 33, 522\u2013533 (2022).","journal-title":"Ann. Oncol."},{"key":"889_CR70","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1038\/s41591-024-03072-w","volume":"30","author":"J Rod\u00f3n","year":"2024","unstructured":"Rod\u00f3n, J. et al. Publisher correction: pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat. Med. 30, 2377 (2024).","journal-title":"Nat. Med."},{"key":"889_CR71","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/2159-8290.CD-14-1205","volume":"5","author":"PS Hammerman","year":"2015","unstructured":"Hammerman, P. S., Hayes, D. N. & Grandis, J. R. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov. 5, 239\u2013244 (2015).","journal-title":"Cancer Discov."},{"key":"889_CR72","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1158\/2767-9764.CRC-24-0137","volume":"4","author":"B Garmezy","year":"2024","unstructured":"Garmezy, B. et al. A phase I study of KIN-3248, an irreversible small-molecule pan-FGFR inhibitor, in patients with advanced FGFR2\/3-driven solid tumors. Cancer Res. Commun. 4, 1165\u20131173 (2024).","journal-title":"Cancer Res. Commun."},{"key":"889_CR73","first-page":"121","volume":"16","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Case report lenvatinib is an effective treatment for refractory nasopharyngeal carcinoma harboring FGFR3-TACC fusion: a case report. In. J. Clin. Exp. Med. 16, 121\u2013126 (2023).","journal-title":"In. J. Clin. Exp. Med."},{"key":"889_CR74","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4143\/crt.2023.433","volume":"56","author":"KH Kim","year":"2024","unstructured":"Kim, K. H. et al. A phase II trial of nintedanib in patients with metastatic or recurrent head and neck squamous cell carcinoma: in-depth analysis of nintedanib arm from the KCSG HN 15-16 TRIUMPH trial. Cancer Res Treat. 56, 37\u201347 (2024).","journal-title":"Cancer Res Treat."},{"key":"889_CR75","doi-asserted-by":"crossref","unstructured":"Guo, Y. et al. Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF\/FGFR gene aberrations. Am. Soc. Clin. Oncol. 39, 4092\u20134092 (2022).","DOI":"10.1200\/JCO.2021.39.15_suppl.4092"},{"key":"889_CR76","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-12-3950","volume":"73","author":"RG Liao","year":"2013","unstructured":"Liao, R. G. et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73, 5195\u20135205 (2013).","journal-title":"Cancer Res."},{"key":"889_CR77","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J. Clin. Investig. 128, 4654\u20134668 (2018).","journal-title":"J. Clin. Investig."},{"key":"889_CR78","doi-asserted-by":"crossref","unstructured":"Quatrini, L. et al. The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers 12, 3285 (2020).","DOI":"10.3390\/cancers12113285"},{"key":"889_CR79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coche.2017.11.006","volume":"19","author":"J Rosenberg","year":"2018","unstructured":"Rosenberg, J. & Huang, J. CD8(+) T cells and NK cells: parallel and complementary soldiers of immunotherapy. Curr. Opin. Chem. Eng. 19, 9\u201320 (2018).","journal-title":"Curr. Opin. Chem. Eng."},{"key":"889_CR80","doi-asserted-by":"crossref","unstructured":"Song, Y., et al., Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J. Immunother Cancer 11, e006643 (2023).","DOI":"10.1136\/jitc-2022-006643"},{"key":"889_CR81","doi-asserted-by":"publisher","first-page":"1030969","DOI":"10.3389\/fimmu.2022.1030969","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. Front. Immunol. 13, 1030969 (2022).","journal-title":"Front. Immunol."},{"key":"889_CR82","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics 12, 4564\u20134580 (2022).","journal-title":"Theranostics"},{"key":"889_CR83","doi-asserted-by":"publisher","first-page":"2021619","DOI":"10.1080\/2162402X.2021.2021619","volume":"11","author":"M Kono","year":"2022","unstructured":"Kono, M. et al. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. Oncoimmunology 11, 2021619 (2022).","journal-title":"Oncoimmunology"},{"key":"889_CR84","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","volume":"82","author":"Y Adachi","year":"2022","unstructured":"Adachi, Y. et al. Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res. 82, 292\u2013306 (2022).","journal-title":"Cancer Res."},{"key":"889_CR85","doi-asserted-by":"publisher","first-page":"974581","DOI":"10.3389\/fimmu.2022.974581","volume":"13","author":"B Zhang","year":"2022","unstructured":"Zhang, B. et al. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Front. Immunol. 13, 974581 (2022).","journal-title":"Front. Immunol."},{"key":"889_CR86","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/cncr.31322","volume":"124","author":"C Fakhry","year":"2018","unstructured":"Fakhry, C. et al. Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals. Cancer 124, 2125\u20132133 (2018).","journal-title":"Cancer"},{"key":"889_CR87","doi-asserted-by":"crossref","unstructured":"Bruno, R. & Fontanini, G. Next generation sequencing for gene fusion analysis in lung cancer: a literature review. Diagnostics 10, 521 (2020).","DOI":"10.3390\/diagnostics10080521"},{"key":"889_CR88","doi-asserted-by":"crossref","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with mutect2. bioRxiv, 861054 (2019).","DOI":"10.1101\/861054"},{"key":"889_CR89","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome. Res. 22, 568\u2013576 (2012).","journal-title":"Genome. Res."},{"key":"889_CR90","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye, K. et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865\u20132871 (2009).","journal-title":"Bioinformatics"},{"key":"889_CR91","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13059-016-1029-6","volume":"17","author":"Y Fan","year":"2016","unstructured":"Fan, Y. et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome. Biol. 17, 178 (2016).","journal-title":"Genome. Biol."},{"key":"889_CR92","doi-asserted-by":"publisher","first-page":"12898","DOI":"10.1038\/s41598-020-69772-8","volume":"10","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. SomaticCombiner: improving the performance of somatic variant calling based on evaluation tests and a consensus approach. Sci. Rep. 10, 12898 (2020).","journal-title":"Sci. Rep."},{"key":"889_CR93","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017, 00011 (2017)."},{"key":"889_CR94","doi-asserted-by":"publisher","first-page":"lqaa078","DOI":"10.1093\/nargab\/lqaa078","volume":"2","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Parmigiani, G. & Johnson, W. E. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom. Bioinform. 2, lqaa078 (2020).","journal-title":"NAR Genom. Bioinform."},{"key":"889_CR95","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/1878-0261.12435","volume":"13","author":"A Khan","year":"2019","unstructured":"Khan, A. et al. Detection of human papillomavirus in cases of head and neck squamous cell carcinoma by RNA-seq and VirTect. Mol. Oncol. 13, 829\u2013839 (2019).","journal-title":"Mol. Oncol."},{"key":"889_CR96","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello, F. et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome. Med. 11, 34 (2019).","journal-title":"Genome. Med."},{"key":"889_CR97","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2326-6066.CIR-18-0342","volume":"6","author":"AJ Nirmal","year":"2018","unstructured":"Nirmal, A. J. et al. Immune cell gene signatures for profiling the microenvironment of solid tumors. Cancer Immunol. Res. 6, 1388\u20131400 (2018).","journal-title":"Cancer Immunol. Res."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00889-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T13:03:17Z","timestamp":1751547797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00889-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-00889-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R. participated in Advisory Boards for Incyte Corporation (2017, 2023), AbbVie, Inc. (2017), QED Therapeutics (2018, 2019), Bayer (2020), Seagen (2023), Tyra Biosciences (2023), Taiho (2024). [Health care companies) (<10,000 USD). S.R. received honoraria from IDT Integrated DNA Technologies (2017), Illumina (2018). [Technology companies]. S.R. received consulting fees from QED Therapeutics (2018, 2019) and Merck (2019). [Health care companies] (<10,000 USD). S.R. received travel reimbursement from Incyte Corporation (2019)(Less than 999 USD). T.W.D. Consulting\/Ad Board; Caris Life Sciences, NEED Inc, Merck & Co., EMD Serono, Adlai Nortye, Genmab, Replimmune; Stock: High EnrollClinical trial funding: Merck & Co., BMS, Janssen, AstraZeneca, Tesaro\/GSK","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}